[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 54 of about 54
1. Ramamoorthy S, Luo L, Luo E, Carethers JM: Tobacco smoking and risk of recurrence for squamous cell cancer of the anus. Cancer Detect Prev; 2008;32(2):116-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tobacco smoking and risk of recurrence for squamous cell cancer of the anus.
  • OBJECTIVE: Squamous cell cancer of the anus is associated with multiple risk factors, including infection with human papillomavirus, immunosuppression, chronic inflammation, and tobacco smoking, although there is little data on these factors for the prediction of recurrent disease.
  • Here, we evaluated the risk of recurrence and mortality of anal carcinoma in association with tobacco smoking.
  • METHODS: We conducted a retrospective review of cases of anal carcinoma from two local hospitals.
  • We obtained information on treatment response and cancer recurrence, as well as tobacco usage from medical records.
  • RESULTS: We identified 64 patients with squamous cell cancer of the anus, and 34 of these (53%) had a tobacco smoking history.
  • Current smokers had higher carcinoma recurrence rates (11/34, 32%) than non-smokers (6/30, 20%).
  • Overall mortality was 33% (21/64), and cancer-related mortality was 23% (15/64).
  • CONCLUSION: Tobacco smoking appears to be associated with anal carcinoma disease recurrence, and is related to increased mortality.
  • This data suggests that patients should be cautioned about tobacco smoking once a diagnosis of anal carcinoma is made in attempt to improve their long-term outcome.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Dec 1;86(11):2337-45 [10590376.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1544-9 [12697879.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Anesth Analg. 1986 Nov;65(11):1186-8 [3767017.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):159-63 [8417381.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Am J Prev Med. 1995 Jul-Aug;11(4):245-50 [7495601.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2428-36 [16634096.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):853-8 [16815535.001]
  • [Cites] Clin Infect Dis. 2000 Sep;31(3):808-12 [11017836.001]
  • (PMID = 18639388.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067287; United States / NIDDK NIH HHS / DK / R24 DK080506; United States / NIDDK NIH HHS / DK / DK067287-01A2; United States / NIDDK NIH HHS / DK / R24 DK080506-01; United States / NIDDK NIH HHS / DK / R01 DK067287-01A2
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS209533; NLM/ PMC3427794
  •  go-up   go-down


2. Seya T, Tanaka N, Shinji S, Yokoi K, Oguro T, Oaki Y, Ishiwata T, Naito Z, Tajiri T: Squamous cell carcinoma arising from recurrent anal fistula. J Nippon Med Sch; 2007 Aug;74(4):319-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma arising from recurrent anal fistula.
  • Here, we report on a patient with squamous cell carcinoma (SCC) arising from recurrent anal fistula.
  • The patient was a 57-year-old woman who had 32-year history of having a recurrent perianal abscesses that ruptured spontaneously.
  • Six months before her admission to our hospital, anal pain developed.
  • Physical examination revealed three external fistulous openings at the two o'clock position, 2 cm from the anal verge.
  • Microscopic examination showed SCC arising from the anal fistula, which was accompanied by vessel invasion.
  • Histopathological examination revealed no remnant cancer tissue or lymph node metastasis.
  • Urological examination revealed urinary bladder cancer, and transurethral resection of the bladder tumor was performed.
  • Histopathological examination revealed transitional cell carcinoma of the urinary bladder.
  • Two years later, the patient died of metastatic urinary bladder cancer, without recurrence of the fistula cancer.
  • Because the patients mother had died of urinary bladder cancer and she herself had metachronous urinary bladder cancer in addition to fistula cancer, we investigated whether microsatellite instability (MSI) and chromosomal instability correlated with fistula cancer development.
  • Our patient had MSI and one of the smallest reported SCCs arising from recurrent anal fistulae.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma, Squamous Cell / etiology. Rectal Fistula / complications
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Female. Humans. Microsatellite Instability. Middle Aged. Neoplasms, Second Primary / pathology. Recurrence. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878704.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Troicki F, Pappas A, Noone R, Denittis A: Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report. J Med Case Rep; 2010;4:67

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report.
  • INTRODUCTION: High-grade anal intraepithelial neoplasia, also referred to as anal squamous carcinoma in-situ, or Bowen's disease of the anus, make up less than 1% of all digestive system cancers in the United States.
  • The treatment of choice is surgical resection with anal mapping.
  • This can compromise the anal sphincter leading to leakage.
  • In this case report, we discuss the efficacy of radiation therapy as a modality to treat post-excisional recurrent Bowen's disease, which may prevent sphincter compromise, leading to improved quality of life.
  • CASE PRESENTATION: An 84-year-old Caucasian woman presented with post-excisional persistent/recurrent squamous cell carcinoma in-situ.
  • The initial lesion measured 3 cm in diameter on the right lateral side of the anal margin.
  • A standard surgery consisting of wide local excision with anal mapping was performed.
  • Our patient recurred with a 1.2 x 0.8 cm lesion on the left anal verge extending to the anal canal.
  • A biopsy along with mapping was done, and 2 of the 17 mapping specimens were positive for carcinoma in-situ, one in the anal canal.
  • Due to the location of the positive anal mapping, and in order to prevent sphincter compromise on re-excision, our patient was offered definitive radiation therapy.
  • Two years after radiation therapy, our patient showed no signs of recurrent disease and had good sphincter control.
  • CONCLUSION: Although the main treatment modality for treating persistent/recurrent Bowen's disease is surgery, an alternative approach using external beam radiation for CIS may be enough to provide a cure for some patients with recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Australas J Dermatol. 2006 May;47(2):120-3 [16637809.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S25-33 [15753009.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] Br J Surg. 1997 May;84(5):675-8 [9171763.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Urol Clin North Am. 1992 Feb;19(1):83-91 [1310549.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • (PMID = 20181236.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2841077
  •  go-up   go-down


Advertisement
4. Nahas SC, Nahas CS, Silva Filho EV, Levi JE, Atui FC, Marques CF: Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report. Sao Paulo Med J; 2007 Sep 6;125(5):292-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report.
  • CONTEXT: Highly active antiretroviral therapy (HAART) has turned human immunodeficiency virus (HIV) infection into a chronic condition, and this has led to increased incidence of anal dysplasia among HIV-positive patients.
  • Routine anal evaluation including the anal canal and perianal area is recommended for this population, especially for patients infected by oncogenic human papillomavirus (HPV) types.
  • CASE REPORT: A 54-year-old homosexual HIV-positive man presented with a six-year history of recurrent perianal and anal warts.
  • He presented some condylomatous spreading lesions occupying part of the anal canal and the perianal skin, and also a well-demarcated slightly painful perianal plaque of dimensions 1.0 x 1.0 cm.
  • Both anal canal Pap smears and biopsies guided by high-resolution anoscopy revealed high-grade squamous intraepithelial lesion.
  • HPV DNA testing of the anus detected the presence of HPV-16 type.
  • Histological analysis on the excised tissue revealed high-grade squamous intraepithelial lesion with one focus of microinvasive squamous cell cancer measuring 1 mm.
  • The patient showed pathological evidence of recurrent anal and perianal high-grade squamous intraepithelial lesions at the sixth-month follow-up and required further ablation of those lesions.
  • However no invasive squamous cell carcinoma recurrence has been detected so far.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / adverse effects. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. HIV Seropositivity / drug therapy. Human papillomavirus 16 / isolation & purification. Papillomavirus Infections / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. DNA, Viral / analysis. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis


5. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Muñoz N, Schiffman M, Bosch FX: Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine; 2008 Aug 19;26 Suppl 10:K17-28
MedlinePlus Health Information. consumer health - Genital Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The association of HPV DNA with several different ano-genital cancers other than cervical has been reported for the vulva, vagina, anus and penis.
  • In men, 80-85% of anal cancers and close to 50% of penile cancers are associated with HPV infection.
  • In women, HPV DNA is prevalent in 36-40% vulvar cancer cases and close to 90% of vaginal cancers.
  • Among HPV DNA positive ano-genital cancer cases, HPV-16 is the most frequently found followed distantly by HPV-18.
  • In benign HPV-related diseases such as genital warts or recurrent respiratory papillomatosis HPV-6 and 11, the two most frequent non-oncogenic types, are the predominant types detected.
  • We summarize the evidence linking HPV in the epidemiology and etiology of cancers of the vulva, vagina, anus and oropharynx and present recent estimates of the burden of and HPV type distribution in genital warts and in cases of HPV infection of the airways.
  • [MeSH-minor] Anus Neoplasms / virology. Female. Humans. Male. Papillomaviridae / immunology. Papillomaviridae / pathogenicity. Respiratory Tract Infections / epidemiology. Respiratory Tract Infections / virology. Uterine Cervical Diseases / epidemiology. Uterine Cervical Diseases / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18847554.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098803
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 91
  • [Other-IDs] NLM/ NIHMS73638; NLM/ PMC4366004
  •  go-up   go-down


6. Grigsby PW: FDG-PET/CT: new horizons in anal cancer. Gastroenterol Clin Biol; 2009 May;33(5):456-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT: new horizons in anal cancer.
  • Anal cancer is an uncommon tumor with an incidence of about one case per 100,000 in most countries.
  • Current treatment guidelines include fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) as part of the standard pretreatment workup of patients diagnosed with anal cancer.
  • This imaging modality can also be used to evaluate sites of recurrent disease.
  • FDG-PET/CT is an imaging modality which greatly affects the management of patients with anal cancer.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394179.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Puglisi M, Varaldo E, Assalino M, Ansaldo G, Torre G, Borgonovo G: Anal metastasis from recurrent breast lobular carcinoma: a case report. World J Gastroenterol; 2009 Mar 21;15(11):1388-90
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal metastasis from recurrent breast lobular carcinoma: a case report.
  • We report a case of isolated gastrointestinal metastasis from breast lobular carcinoma, which mimicked primary anal cancer.
  • In July 2000, an 88-year-old woman presented with infiltrating lobular cancer (pT1/G2/N2).
  • Four years later, she presented with an anal polypoid lesion.
  • [MeSH-major] Anus Neoplasms / secondary. Breast Neoplasms / pathology. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):211-5 [1434649.001]
  • [Cites] Surgery. 1993 Oct;114(4):637-41; discussion 641-2 [8211676.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):338-47 [15737028.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1745-50 [16721370.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):453-5 [11289296.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):71-3 [12488295.001]
  • [Cites] Ann Chir. 1983 May;37(4):281-4 [6625502.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):307-10 [3954484.001]
  • [Cites] Int J Biol Markers. 1988 Jan-Mar;3(1):41-8 [2854832.001]
  • [Cites] Tech Coloproctol. 2005 Dec;9(3):237-8 [16328121.001]
  • (PMID = 19294770.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2658842
  •  go-up   go-down


8. Christensen AF, Nyhuus B, Nielsen MB: Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer. Dis Colon Rectum; 2009 Mar;52(3):484-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer.
  • PURPOSE: This study was designed to evaluate the interobserver and intraobserver agreement of two-dimensional (2-D) and three-dimensional (3-D) anal endosonography for the detection of local recurrence anal carcinoma.
  • METHODS: Thirty-six patients were treated for anal carcinoma, and seven had recurrent disease.
  • CONCLUSIONS: Three-dimensional endosonography proved to have significantly better interobserver and intraobserver agreement than 2-D endosonography concerning detection of recurrent anal cancer.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Endosonography. Neoplasm Recurrence, Local / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / ultrasonography. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Observer Variation. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333050.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Christensen AF, Nielsen MB, Svendsen LB, Engelholm SA: Three-dimensional anal endosonography may improve detection of recurrent anal cancer. Dis Colon Rectum; 2006 Oct;49(10):1527-32
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional anal endosonography may improve detection of recurrent anal cancer.
  • PURPOSE: In our center since 2001, follow-up examination has included three-dimensional endosonography in all patients with suspicion of local recurrence of anal cancer.
  • METHODS: This prospective study included 38 consecutive patients who have had anal carcinoma and were investigated using three-dimensional endosonography in combination with anoscopy and digital rectal examination at Rigshospitalet from July 2001 to January 2005 under suspicion of local recurrence.
  • CONCLUSIONS: This study indicates that three-dimensional endosonography surpasses two-dimensional endosonography in the evaluation of patients with suspicion of local recurrence of anal cancer especially in combination with anoscopy and digital rectal examination.
  • [MeSH-major] Anal Canal / ultrasonography. Anus Neoplasms / ultrasonography. Endosonography / methods. Imaging, Three-Dimensional. Neoplasm Recurrence, Local / ultrasonography

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988854.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Chen YW, Yen SH, Chen SY, Huang PI, Shiau CY, Liu YM, Lin JK, Wang LW: Anus-preservation treatment for anal cancer: retrospective analysis at a single institution. J Surg Oncol; 2007 Oct 1;96(5):374-80
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
  • BACKGROUND: To evaluate anus-preservation treatment for anal cancer.
  • METHODS: Review of 42 patients (24 M/18 F; median age, 70 years; range, 13-95) with stage I-IIIB disease (squamous cell carcinoma [SqCC], 33; adenocarcinoma, 9) who received curative radiotherapy between 1991 and 2004.
  • The complete response rate was 67% (SqCC, 23/33; adenocarcinoma, 5/9); of 12 patients who failed treatment, primary tumor was the recurrent site in seven (median failure time, 5 months): six patients underwent salvage abdominoperineal resection.
  • Five-year functional anus-preservation rate was 64%.
  • CONCLUSION: With careful monitoring of toxicity, non-surgical anus-preservation treatment with good tumor control is feasible.
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17492635.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Ferenschild FT, Vermaas M, Hofer SO, Verhoef C, Eggermont AM, de Wilt JH: Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg; 2005 Nov;29(11):1452-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer.
  • The primary treatment for anal cancer is chemoradiation (CRT).
  • A major problem of surgery in the anal area is poor healing of the perineal wound.
  • Between 1985 and 2000, 129 patients treated for anal cancer were retrospectively reviewed.
  • In the present study salvage APR in recurrent or persistent anal cancer results in good local control and 5-year overall survival of 30%.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Salvage Therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222445.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Patel CB, Ramos-Valadez DI, Haas EM: Robotic-assisted laparoscopic abdominoperineal resection for anal cancer: feasibility and technical considerations. Int J Med Robot; 2010 Dec;6(4):399-404
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic-assisted laparoscopic abdominoperineal resection for anal cancer: feasibility and technical considerations.
  • BACKGROUND: Robotic-assisted laparoscopic surgery is an emerging technology that may prove advantageous for complex colorectal procedures involving the irradiated pelvis, such as abdominoperineal resection for recurrent anal cancer.
  • METHODS: Over a 6 month period, five abdominoperineal resections were performed using the da Vinci® robot for recurrent anal cancer in patients initially treated with definitive chemoradiation therapy.
  • CONCLUSION: Robotic-assisted laparoscopic surgery for anal cancer was found to be a safe and feasible procedure.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Laparoscopy / methods. Perineum / surgery. Robotics / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20827795.001).
  • [ISSN] 1478-596X
  • [Journal-full-title] The international journal of medical robotics + computer assisted surgery : MRCAS
  • [ISO-abbreviation] Int J Med Robot
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Vietharsdóttir H, Moeller PH, Jóhannsson J, Jónasson JG: [Anal cancer in Iceland 1987-2003. A population based study]. Laeknabladid; 2006 May;92(5):365-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer in Iceland 1987-2003. A population based study].
  • [Transliterated title] Carcinoma ani á Islandi 1987-2003 -- lýethgrundueth rannsókn.
  • OBJECTIVE: Anal cancer is a rare disease.
  • The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.
  • MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.
  • This is a nationwide, population-based study of malignant tumours of the anal region.
  • RESULTS: From 1987-2003 thirty-eight patients were diagnosed with anal cancer, 28 females and 10 males.
  • Age standardized incidence rates for anal cancer in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.
  • Most patients had squamous cell carcinoma (n=30).
  • The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).
  • Twelve patients had recurrent cancer.
  • The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).
  • Sixteen patients remain with disease and ten have died of anal cancer.
  • The five year survival rate for patients diagnosed in the years 1987 to 1998 is 75% but cancer-specific survival is 82%.
  • CONCLUSION: Age-standardized incidence for anal cancer in Iceland is similar to other regions.
  • The proportion of adenocarcinoma of the anus is lower in Iceland than elsewhere.
  • [MeSH-major] Anus Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741319.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


14. Mariani P, Ghanneme A, De la Rochefordière A, Girodet J, Falcou MC, Salmon RJ: Abdominoperineal resection for anal cancer. Dis Colon Rectum; 2008 Oct;51(10):1495-501
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominoperineal resection for anal cancer.
  • PURPOSE: Following initial radiotherapy or chemoradiotherapy for the treatment of anal cancer, patients who present with either persistent or locally recurrent disease are treated by abdominoperineal resection.
  • METHODS: Over a 34-year period (1969-2003), 422 patients with nonmetastatic anal cancer were treated with a curative intent.
  • RESULTS: Forty-one patients underwent abdominoperineal resection for persistent disease and 42 for locally recurrent disease.
  • Surgery, whether for persistent or locally recurrent disease, did not affect the 5-year survival rate.
  • CONCLUSIONS: Abdominoperineal resection for nonmetastatic anal cancer is associated with a high morbidity rate but may result in long-term survival regardless of the indication.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Perineum / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521675.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Rinaldi M, Cormio G, Bucaria V, Di Tonno P, Marino F, Altomare DF: [Reconstruction with skin flaps of the posterior aspect of the thighs after total pelvic evisceration with removal of vulvo-perineal soft tissues in recurrent vulvar squamous carcinoma]. Suppl Tumori; 2005 May-Jun;4(3):S208
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reconstruction with skin flaps of the posterior aspect of the thighs after total pelvic evisceration with removal of vulvo-perineal soft tissues in recurrent vulvar squamous carcinoma].
  • [Transliterated title] Ricostruzione con lembi cutanei della faccia posteriore delle cosce dopo evisceratio pelvica totale con asportazione dei tessuti molli vulvo-perineali per carcinoma squamoso vulvare recidivo.
  • We report of a case of a fortythree years old women affected by squamous cell cancer of the vulva (T3N0M0).
  • Because of local diffusion with infiltration of the urethra and anus, the patient was submitted to demolitive operation (total pelvic evisceratio, excision of pelvic and perineal soft tissues and reconstruction with rotating skin flaps of the posterior face of the thighs).
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Pelvic Exenteration. Perineum. Reconstructive Surgical Procedures / methods. Soft Tissue Neoplasms / surgery. Surgical Flaps. Thigh / surgery. Vulvar Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437992.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Sunesen KG, Buntzen S, Tei T, Lindegaard JC, Nørgaard M, Laurberg S: Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Ann Surg Oncol; 2009 Jan;16(1):68-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap.
  • Salvage surgery of recurrent or persistent anal cancer following radiotherapy is often followed by perineal wound complications.
  • We examined survival and perineal wound complications in anal cancer salvage surgery during a 10-year period with primary perineal reconstruction predominantly performed using vertical rectus abdominis myocutaneous (VRAM) flap.
  • Between 1997 and 2006, 49 patients underwent anal cancer salvage surgery.
  • We conclude that anal cancer salvage surgery can yield long-time survival but obtaining free margins is critical.
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / surgery. Perineum / surgery. Reconstructive Surgical Procedures. Rectus Abdominis / transplantation. Surgical Flaps. Wound Healing
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Postoperative Complications / diagnosis. Postoperative Complications / therapy. Salvage Therapy. Survival Rate. Time Factors. Treatment Outcome


17. Schiller DE, Cummings BJ, Rai S, Le LW, Last L, Davey P, Easson A, Smith AJ, Swallow CJ: Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol; 2007 Oct;14(10):2780-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of salvage surgery for squamous cell carcinoma of the anal canal.
  • BACKGROUND: For patients with anal canal cancer who fail combined modality treatment (CMT), salvage surgery (SS) offers the potential for long term survival.
  • METHODS: We identified 60 patients with persistent or recurrent anal cancer who had undergone SS; 20 were excluded.
  • CONCLUSION: SS for anal canal cancer was associated with significant morbidity.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Anal Canal / surgery. Cancer Care Facilities. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Ontario. Registries. Reoperation. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638059.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Hamada M, Ozaki K, Iwata J, Nishioka Y, Horimi T: A case of rectosigmoid cancer metastasizing to a fistula in ano. Jpn J Clin Oncol; 2005 Nov;35(11):676-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rectosigmoid cancer metastasizing to a fistula in ano.
  • We herein report a case of rectosigmoid cancer metastasizing to a fistula in ano.
  • A 53-year-old man complaining of anal bleeding consulted another hospital.
  • He had been suffering from an anal fistula since 7 years.
  • On the left upper side of the skin surface around the anus a fistula end was seen as a hole that tunneled down into the back passage, although no hard tumor was palpable on the hole.
  • The post-operative pathological diagnosis was rectosigmoid cancer, Type 2, T2, N0, M0, stage II.
  • The anal fistula was a simple type and mucinous discharge was not observed.
  • On 23 February 2004, coring out the anal fistula was performed by the former hospital.
  • We diagnosed this tumor as metastatic adenocarcinoma from a rectosigmoid cancer.
  • Recurrent lesions were not seen during the first year after the first operation.
  • [MeSH-major] Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Humans. Lymph Node Excision. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275674.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM: Magnetic resonance imaging of anal cancer. Clin Radiol; 2005 Oct;60(10):1111-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of anal cancer.
  • AIM: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) appearances of primary and recurrent anal carcinoma, and to demonstrate the commonest patterns of local and distant disease spread.
  • METHODS: A retrospective review was performed of 27 cases of biopsy-proven anal carcinoma, where MRI was used for primary staging (9 patients) or suspected recurrence (18 patients).
  • The size, extent and signal characteristics of the anal tumour were documented.
  • In all, 7 patients with recurrent disease underwent surgery and subsequent histological correlation was performed.
  • RESULTS: Primary and recurrent tumours were of high signal intensity relative to skeletal muscle on T2-weighted images (T2WI), and of low to intermediate signal intensity on T1-weighted images (T1WI).
  • Lymph node metastases were of similar signal intensity to the anal cancer.
  • Recurrent tumours were more locally advanced than primary tumours and extended into adjacent organs and the pelvic skeleton.
  • Recurrent lymph node disease involved perirectal, presacral and internal iliac nodes more commonly than did primary lymph node disease.
  • MR has a role in the preoperative evaluation and surgical planning of cases of recurrent disease following radiotherapy.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179172.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Stewart D, Yan Y, Kodner IJ, Birnbaum E, Fleshman J, Myerson R, Dietz D: Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg; 2007 Dec;11(12):1744-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?
  • It is common belief that patients failing chemoradiation therapy (CRT) for squamous cell cancer of the anus (SCCA) can be salvaged with subsequent surgery.
  • The aim of this study was to examine our experience with abdominoperineal resection (APR) in cases of persistent or recurrent SCCA with an emphasis on survival and morbidity.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy


22. Kidd EA, Dehdashti F, Siegel BA, Grigsby PW: Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol; 2010 Jun;95(3):288-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis.
  • PURPOSE: To evaluate anal cancer uptake of F-18 fluorodeoxyglucose (FDG) measured as the maximum standardized uptake value (SUV(max)) by positron emission tomography (PET) and its correlation with prognostic factors.
  • PATIENTS AND METHODS: The study population consisted of 77 patients with stages 0-IIIB anal cancer who underwent pre-treatment FDG-PET.
  • Patients with high anal tumor SUV(max) at diagnosis were at an increased risk of persistent or recurrent disease on post-therapy FDG-PET performed less than 4months after completing therapy (p=0.0402).
  • CONCLUSIONS: SUV(max) is a valuable biomarker of anal cancer prognosis, predicting increased risk of lymph node metastasis and worse disease-free survival.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacokinetics. Positron-Emission Tomography. Radiopharmaceuticals / pharmacokinetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20231040.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Hogg ME, Popowich DA, Wang EC, Kiel KD, Stryker SJ, Halverson AL: HIV and anal cancer outcomes: a single institution's experience. Dis Colon Rectum; 2009 May;52(5):891-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV and anal cancer outcomes: a single institution's experience.
  • PURPOSE: The purpose of this study is to identify the effect of HIV status on outcome of treatment for squamous-cell carcinoma of the anal canal.
  • METHODS: A retrospective review was performed on all patients with squamous-cell carcinoma of the anal canal treated at a single academic institution between January 1996 and December 2006.
  • RESULTS: Our search identified 87 (21 HIV-positive) patients who had invasive squamous-cell cancer.
  • Eight percent of HIV-negative and 29 percent of HIV-positive patients developed recurrent disease after 6 months (P = 0.0009).
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality. HIV Infections / mortality


24. Mai SK, Welzel G, Hermann B, Bohrer M, Wenz F: Long-term outcome after combined radiochemotherapy for anal cancer - retrospective analysis of efficacy, prognostic factors, and toxicity. Onkologie; 2008 May;31(5):251-7
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome after combined radiochemotherapy for anal cancer - retrospective analysis of efficacy, prognostic factors, and toxicity.
  • BACKGROUND: This retrospective study evaluated the efficacy, prognostic factors, and toxicity of combined radiochemotherapy for anal cancer.
  • Higher T category was associated with inferior prognosis for colostomy-free survival (p = 0.000), male sex for local control (p = 0.004) and diseasespecific survival (p = 0.002), and tumor site at the anal margin for local control (p = 0.03).
  • 4 of 7 patients with recurrent anal margin tumors had human papillomavirus (HPV)-related disease.
  • CONCLUSION: Combined radiochemotherapy for anal cancer is a highly effective therapy with pronounced acute and minor late toxicity.
  • In the case of higher T stage, male sex, and cancer at the anal margin, treatment intensification should be considered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Anus Neoplasms / therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Radiotherapy / mortality. Risk Assessment / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18497514.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


25. Zampino MG, Magni E, Sonzogni A, Renne G: K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol; 2009 Dec;65(1):197-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?
  • PURPOSE: Squamous cell anal carcinoma (SCC) is an uncommon disease comprising only 1-5% of all intestinal tumours.
  • The EGFR status and k-ras mutations in SCC of the anal canal has not been well investigated.
  • This observation previously reported in other tumours has supported the effective use of EGFR-inhibitors in recurrent or metastatic disease.
  • [MeSH-major] Anus Neoplasms / genetics. Carcinoma, Squamous Cell / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727729.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


26. Jethwa P, Lake SP: Using topical negative pressure therapy to resolve wound failure following perineal resection. J Wound Care; 2005 Apr;14(4):166-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elective resection of the rectum and perineum in a patient with recurrent squamous cell carcinoma of the anus resulted in significant wound failure.
  • Full healing was achieved with topical negative pressure, with no recurrence of the cancer.
  • [MeSH-minor] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Humans. Male. Middle Aged. Recurrence. Suction / methods. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15835227.001).
  • [ISSN] 0969-0700
  • [Journal-full-title] Journal of wound care
  • [ISO-abbreviation] J Wound Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Rouquie D, Lasser P, Castaing M, Boige V, Goéré D, Pignon JP, Ducreux M, Elias D, Pocard M: [Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients)]. J Chir (Paris); 2008 Jul-Aug;145(4):335-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients)].
  • [Transliterated title] Résection R0, seul facteur pronostique dans les amputations abdominopérinéales de rattrapage des cancers du canal anal (série consécutive de 95 patients).
  • INTRODUCTION: When radiation therapy fails to control cancer of the anal canal, the only therapeutic alternative is salvage abdomino-perineal resection (APR).
  • CONCLUSION: When anal cancer recurs after radiation therapy, a salvage APR is indicated.

  • Genetic Alliance. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955923.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


28. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum; 2008 Jun;51(6):829-35; discussion 835-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience.
  • PURPOSE: This study was designed to determine whether high-resolution anoscopy and targeted surgical destruction of anal high-grade squamous intraepithelial lesions is effective in controlling high-grade squamous intraepithelial lesions while preserving normal tissues.
  • Recurrent high-grade squamous intraepithelial lesions occurred in 114 patients (57 percent) at an average 19 (range, 3-92) months; 26 of these required surgery.
  • Despite treatment, three patients progressed to invasive cancer (1.2 percent).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Proctoscopy

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363070.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Hu D, Goldie S: The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol; 2008 May;198(5):500.e1-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this study was (1) to estimate the direct medical costs of 7 major noncervical human papillomavirus (HPV)-related conditions that include genital cancers, mouth and oropharyngeal cancers, anogenital warts, and juvenile-onset recurrent respiratory papillomatosis, and (2) to approximate the economic burden of noncervical HPV disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2001 Nov;37(17):2204-11 [11677108.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1211-8 [11583947.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1397-403 [12766834.001]
  • [Cites] Chronic Dis Can. 2003 Fall;24(4):91-101 [14733758.001]
  • [Cites] Perspect Sex Reprod Health. 2004 Jan-Feb;36(1):11-9 [14982672.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Am J Dis Child. 1991 Jul;145(7):729-33 [1905479.001]
  • [Cites] Med Care. 1994 Jul;32(7 Suppl):JS77-89 [8028415.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91 [7488368.001]
  • [Cites] Obstet Gynecol. 1996 Jan;87(1):59-64 [8532267.001]
  • [Cites] Obstet Gynecol. 1997 Jan;89(1):81-4 [8990443.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] Am J Manag Care. 1999 Jan;5(1):69-77 [10345969.001]
  • [Cites] Med Decis Making. 2004 Nov-Dec;24(6):584-601 [15534340.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Nov;130(11):1269-75 [15545580.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] Pharmacoeconomics. 2005;23(11):1107-22 [16277547.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):1111-5 [16469634.001]
  • [Cites] Health Technol Assess. 2006 Apr;10(14):1-144, iii-iv [16707071.001]
  • [Cites] Obstet Gynecol Surv. 2006 Jun;61(6 Suppl 1):S3-14 [16729902.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25 [16949997.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/114-21 [16949998.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41 [16950016.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S7-27 [17161169.001]
  • [Cites] Am J Obstet Gynecol. 2007 Mar;196(3):206-12 [17346523.001]
  • [Cites] Gynecol Oncol. 2002 Feb;84(2):263-70 [11812085.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Clin Infect Dis. 2000 Jul;31(1):107-9 [10913405.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Aug;126(8):935-9 [10922223.001]
  • [Cites] Arch Dermatol. 2001 Mar;137(3):337-41 [11255335.001]
  • [CommentIn] Am J Obstet Gynecol. 2008 May;198(5):487-8 [18455522.001]
  • (PMID = 18455524.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093435-04A1; United States / CIT NIH HHS / CT / 1406-04-07-CT-66327; United States / NCI NIH HHS / CA / R01 CA093435; United States / NCI NIH HHS / CA / R01 CA093435-04A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  • [Other-IDs] NLM/ NIHMS49997; NLM/ PMC2441758
  •  go-up   go-down


30. Kumar GK, Chandra SS, Krishnan R: Local excision inadequate in the treatment of anal canal leiomyosarcoma. Saudi J Gastroenterol; 2010 Jul-Sep;16(3):226-7
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local excision inadequate in the treatment of anal canal leiomyosarcoma.
  • Leiomyosarcoma of the anal canal is an uncommon neoplasm of the gastrointestinal tract.
  • We report a 45-year-old lady with anal canal leiomyosarcoma.
  • In the setting of a recurrent tumor with high-grade histological appearance, local excision would be deemed unsafe.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / surgery. Leiomyosarcoma / surgery

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Surg. 1993 Sep;63(9):703-9 [8363480.001]
  • [Cites] J Chir (Paris). 1988 Apr;125(4):245-8 [3392131.001]
  • [Cites] Postgrad Med J. 1996 May;72(847):304-6 [8761508.001]
  • [Cites] J Med Assoc Ga. 1991 Dec;80(12):685-99 [1800593.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1640-3 [1893364.001]
  • (PMID = 20616423.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3003215
  •  go-up   go-down


31. Leblanc J, Kongkam P: Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Diagnosis of Recurrent Anal Cancer After Chemoradiation and Negative Forceps Biopsies: A Case Report. Clin Med Oncol; 2009;3:59-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Diagnosis of Recurrent Anal Cancer After Chemoradiation and Negative Forceps Biopsies: A Case Report.
  • A 69-year-old woman with a history of uT2 N0 post-treated anal squamous cell cancer (SCC) presented for EUS for perianal pain.
  • A sigmoidoscopy revealed mild narrowing of the anal canal and an ulcerated friable mucosa in the same area.
  • While endoscopic biopsy of suspected anal recurrences is usually sufficient, histologic or cytologic confirmation are necessary, as radiation-induced changes are difficult to differentiate from tumor recurrence.
  • This case demonstrates that EUS-FNA is useful in surveillance of anal SCC when there is a high clinical suspicion of recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1996 Jul;91(7):1309-11 [8677984.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):906-12 [10201455.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):346-50 [12594671.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):940-7 [15329901.001]
  • [Cites] Cancer Invest. 2006 Aug-Sep;24(5):535-44 [16939964.001]
  • (PMID = 20689610.001).
  • [ISSN] 1177-9314
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2872600
  •  go-up   go-down


32. Kim JJ, Goldie SJ: Health and economic implications of HPV vaccination in the United States. N Engl J Med; 2008 Aug 21;359(8):821-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the health benefits of averting other HPV-16-related and HPV-18-related cancers, the prevention of HPV-6-related and HPV-11-related genital warts and juvenile-onset recurrent respiratory papillomatosis by means of the quadrivalent vaccine, the duration of immunity, and future screening practices.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Massachusetts Medical Society
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):101-5 [12838308.001]
  • [Cites] JAMA. 2003 Aug 13;290(6):781-9 [12915431.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Nov;83(2):237-47 [14631934.001]
  • [Cites] Obstet Gynecol. 2004 Feb;103(2):304-9 [14754700.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):355-60 [15006908.001]
  • [Cites] Obstet Gynecol. 2004 Apr;103(4):619-31 [15051550.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):604-15 [15100338.001]
  • [Cites] Value Health. 2004 Sep-Oct;7(5):518-28 [15367247.001]
  • [Cites] Vaccine. 2004 Oct 22;22(31-32):4215-27 [15474711.001]
  • [Cites] Med Decis Making. 1993 Apr-Jun;13(2):89-102 [8483408.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91 [7488368.001]
  • [Cites] Med Care. 1998 Jun;36(6):778-92 [9630120.001]
  • [Cites] Emerg Infect Dis. 2004 Nov;10(11):1915-23 [15550200.001]
  • [Cites] Lancet. 2005 Sep 17-23;366(9490):991-8 [16168781.001]
  • [Cites] Adv Data. 2005 Sep 15;(362):1-55 [16250464.001]
  • [Cites] Pharmacoeconomics. 2005;23(11):1107-22 [16277547.001]
  • [Cites] Vaccine. 2005 Dec 1;23(48-49):5624-31 [16099079.001]
  • [Cites] Obstet Gynecol. 2006 Jan;107(1):18-27 [16394035.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1247-55 [16631880.001]
  • [Cites] PLoS Med. 2006 May;3(5):e138 [16573364.001]
  • [Cites] Epidemiol Rev. 2006;28:88-100 [16740585.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/171-7 [16844268.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/106-13 [16949996.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25 [16949997.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/26-34 [16950015.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41 [16950016.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28 [17237032.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):34-40 [17262799.001]
  • [Cites] JAMA. 2007 Feb 28;297(8):813-9 [17327523.001]
  • [Cites] Emerg Infect Dis. 2007 Jan;13(1):28-41 [17370513.001]
  • [Cites] Lancet Infect Dis. 2007 Apr;7(4):289-96 [17376386.001]
  • [Cites] MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 [17380109.001]
  • [Cites] Natl Vital Stat Rep. 2006 Dec 28;55(11):1-18 [17432301.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Lancet. 2007 Jun 2;369(9576):1861-8 [17544766.001]
  • [Cites] Am J Epidemiol. 2007 Jul 15;166(2):137-50 [17526866.001]
  • [Cites] Vaccine. 2007 Jul 20;25(29):5399-408 [17561316.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-70 [17602732.001]
  • [Cites] Vaccine. 2007 Aug 14;25(33):6257-70 [17606315.001]
  • [Cites] Vaccine. 2007 Aug 14;25(33):6245-56 [17630049.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Aug 31;56(34):885-8 [17728694.001]
  • [Cites] Am J Obstet Gynecol. 2007 Oct;197(4):346-55 [17904957.001]
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1322-8 [17923869.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 5;100(5):308-20 [18314477.001]
  • [Cites] Am J Obstet Gynecol. 2008 May;198(5):500.e1-7 [18455524.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Aug;126(8):935-9 [10922223.001]
  • [Cites] MMWR Recomm Rep. 2001 Nov 9;50(RR-19):1-57; quiz CE1-19a1-CE6-19a1 [11718472.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):705-11 [11875730.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] Epidemiology. 2002 Nov;13(6):631-9 [12410003.001]
  • [Cites] CA Cancer J Clin. 2002 Nov-Dec;52(6):342-62 [12469763.001]
  • [Cites] Emerg Infect Dis. 2003 Jan;9(1):37-48 [12533280.001]
  • [Cites] Am J Epidemiol. 2003 Feb 1;157(3):218-26 [12543621.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1397-403 [12766834.001]
  • [CommentIn] N Engl J Med. 2008 Aug 21;359(8):861-2 [18716305.001]
  • (PMID = 18716299.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093435-04A1; United States / NCI NIH HHS / CA / R01 CA093435; United States / NCI NIH HHS / CA / R01 CA093435-04A1; United States / NCI NIH HHS / CA / R01 CA93435
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Other-IDs] NLM/ NIHMS115768; NLM/ PMC3080183
  •  go-up   go-down


33. Heyn J, Placzek M, Ozimek A, Baumgaertner AK, Siebeck M, Volkenandt M: Malignant melanoma of the anal region. Clin Exp Dermatol; 2007 Sep;32(5):603-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma of the anal region.
  • Malignant melanoma (MM) of the anal region is an uncommon disease.
  • Anorectal melanomas (AM) are most common in the rectum, followed by the anal canal and anal verge.
  • We report on a 39-year old man who presented with a 5-week history of recurrent prolapse of an anal tumour.
  • [MeSH-major] Anus Neoplasms. Melanoma
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / therapeutic use. Cancer Vaccines / therapeutic use. Diagnosis, Differential. Humans. Interferon-alpha / therapeutic use. Male. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376215.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cancer Vaccines; 0 / Interferon-alpha
  • [Number-of-references] 25
  •  go-up   go-down


34. Rakoto-Ratsimba HN, Rakototiana AF, Rakotosamimanana J, Ranaivozanany A: [Anal adenocarcinoma revealed by a fistula-in-ano. Report of a case]. Ann Chir; 2006 Nov;131(9):564-6
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal adenocarcinoma revealed by a fistula-in-ano. Report of a case].
  • [Transliterated title] Fistule périanale révélatrice d'un adénocarcinome du canal anal. A propos d'une observation.
  • Anal adenocarcinoma revealed by a fistula-in-ano occurs rarely.
  • Recurrent or non recurrent fistula-in-ano requires multiple biopsies for pathology analysis in order to screen a related cancer.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Anus Neoplasms / complications. Anus Neoplasms / diagnosis. Rectal Fistula / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712770.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


35. Clark J, Cleator S, Goldin R, Lowdell C, Darzi A, Ziprin P: Treatment of primary rectal squamous cell carcinoma by primary chemoradiotherapy: should surgery still be considered a standard of care? Eur J Cancer; 2008 Nov;44(16):2340-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary rectal squamous cell carcinoma by primary chemoradiotherapy: should surgery still be considered a standard of care?
  • Rectal squamous cell carcinoma is a rare tumour accounting for only 0.25% of all rectal carcinomas, yet it carries a significant mortality and morbidity.
  • Radical surgery has been advocated as the primary treatment modality with or without adjunctive therapies despite the proven benefits of primary chemoradiotherapy for squamous cell carcinoma (SCC) of the anus.
  • This report describes 7 cases of rectal squamous cell carcinoma from a single institution over a four-year period, treated with primary chemoradiotherapy.
  • Primary chemoradiotherapy can achieve excellent local control for rectal squamous cell carcinoma with surgery employed only for unresponsive or recurrent tumours.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707873.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Sasaki S, Kojima T, Hidemura A, Hatanaka K, Uekusa T, Ishimaru M: [A case report of anorectal malignant melanoma showing a complete response after DTIC/ACNU/VCR therapy]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1999-2002
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer cells were found in regional lymph nodes.
  • However, malignant melanoma cells were found in hernia contents at the operation for left inguinal hernia, which led to a diagnosis of recurrent malignant melanoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Dacarbazine / therapeutic use. Melanoma / drug therapy. Nimustine / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948273.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


37. Vorob'ev GI, Shelygin IuA, Nechushkin MI, Rybakov EG: [Results of surgical treatment of residual and recurrent anal tumors]. Khirurgiia (Mosk); 2008;(8):4-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of surgical treatment of residual and recurrent anal tumors].
  • Radio- or chemotherapy is a modern standard of anal cancer treatment.
  • The study is aimed to evaluate the role of abdominoperineal resection in the treatment of residual and recurrent anal cancer.
  • The complete tumor regression after radiotherapy/radiochemotherapy was achieved in 74(61.1%) of 120 patients with cancer-specific survival rate of 81.7%.
  • Thus, abdominoperineal resection remains the method of choice in the treatment of residual and recurrent anal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833142.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


38. Füredi G, Szilágyi A, Gilde K, Lövey J, Altorjay A: [Primary anorectal melanoma--an uncommon disease with a poor prognosis]. Magy Seb; 2005 Oct;58(5):337-40
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Primer anorektális melanoma--egy ritka, de igen rossz prognózisú betegség.
  • The majority of patients develop generalised recurrent disease and die despite radical surgical treatment.
  • Screening for colorectal cancer may help to detect this disease earlier and the early diagnosis should give better outcome.
  • [MeSH-major] Anus Neoplasms. Melanoma. Rectal Neoplasms

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16496780.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


39. Hatoum OA, Binion DG, Phillips SA, O'Loughlin C, Komorowski RA, Gutterman DD, Otterson MF: Radiation induced small bowel "web" formation is associated with acquired microvascular dysfunction. Gut; 2005 Dec;54(12):1797-800
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These webs are likely to play a role in the pathogenesis of recurrent bowel obstruction.
  • METHODS: A 40 year old patient treated with radiation, two years previously, for an anal squamous cell cancer presented with recurrent small bowel obstruction.
  • [MeSH-minor] Adult. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Microcirculation / physiopathology. Microcirculation / radiation effects

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1986 Apr;10(2):155-70 [3705602.001]
  • [Cites] Cancer. 1975 Jun;35(6):1633-40 [1148997.001]
  • [Cites] J Clin Pathol. 1988 May;41(5):516-26 [3384981.001]
  • [Cites] Pathol Annu. 1988;23 Pt 1:297-330 [3387138.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):865-9 [1914719.001]
  • [Cites] N Engl J Med. 1992 Sep 10;327(11):749-54 [1501650.001]
  • [Cites] Gastroenterology. 1993 Jun;104(6):1832-47 [8500743.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1213-36 [7713784.001]
  • [Cites] Circ Res. 1998 Sep 7;83(5):501-7 [9734472.001]
  • [Cites] Free Radic Biol Med. 1998 Nov 1;25(7):826-31 [9823548.001]
  • [Cites] AMA Arch Intern Med. 1955 Jul;96(1):26-31 [14387317.001]
  • [Cites] Trends Cardiovasc Med. 2003 Jul;13(5):201-6 [12837583.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):58-69 [12851871.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1185-9 [12714439.001]
  • [Cites] Surgery. 2004 Oct;136(4):854-60 [15467672.001]
  • [Cites] World J Surg. 1986 Apr;10(2):171-88 [3518250.001]
  • (PMID = 16127018.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1774807
  •  go-up   go-down


40. Lucha PA Jr, Fticsar JE, Francis MJ: The strictured anastomosis: successful treatment by corticosteroid injections--report of three cases and review of the literature. Dis Colon Rectum; 2005 Apr;48(4):862-5
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The reported rate averages 8 percent and has been attributed to tissue ischemia, localized sepsis, anastomotic leak, proximal fecal diversion, radiation injury, inflammatory bowel disease, and recurrent rectal cancer.
  • Those patients with loop ileostomies had them taken down and all have been followed for up to 12 months without clinical or endoscopic evidence of recurrent stricture.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Anus Diseases / surgery. Colonic Diseases / surgery. Ileostomy / methods. Postoperative Complications

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15747075.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


41. Dasbach EJ, Elbasha EH, Insinga RP: Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev; 2006;28:88-100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with human papillomavirus (HPV) is the primary cause of cervical cancer, other anogenital cancers, genital warts, and recurrent respiratory papillomatosis.
  • Clinical studies have demonstrated that a prophylactic HPV vaccine can prevent infection, genital warts, and the precancerous lesions that lead to cervical cancer.
  • All have demonstrated that vaccination can significantly reduce the incidence of cervical cancer in the long term.
  • However, only the cohort and hybrid models have evaluated the cost-effectiveness of vaccination strategies for preventing cervical cancer.
  • None has accounted for the potential benefits of vaccinating the population to reduce the burden of recurrent respiratory papillomatosis and cancers of the vagina, vulva, anus, penis, and head/neck.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740585.001).
  • [ISSN] 0193-936X
  • [Journal-full-title] Epidemiologic reviews
  • [ISO-abbreviation] Epidemiol Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 75
  •  go-up   go-down


42. Lee J, Corman M: Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature. J Gastrointest Surg; 2009 Jan;13(1):150-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature.
  • INTRODUCTION: Tumors arising from the anal canal are rare, comprising 1.5% of all gastrointestinal tumors in the USA.
  • The vast majority of these anal cancers are epidermoid (cloacogenic/basaloid and squamous cell carcinomas), while adenocarcinomas reportedly occur 5% to 19% of the time.
  • Because of its rarity, reports about anal adenocarcinoma are limited to small retrospective studies and case reports.
  • Moreover, no series has directly compared outcomes between patients undergoing the various available treatment options, making it difficult to determine the optimal treatment for this aggressive cancer.
  • Current management of this cancer remains controversial, with some authors believing abdominoperineal resection with permanent colostomy should be considered the standard treatment.
  • CASE PRESENTATION: We describe a case of recurrent anal adenocarcinoma after conservative management with local excision and adjuvant chemoradiation therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Agents / therapeutic use. Anus Neoplasms / pathology. Anus Neoplasms / therapy. Colectomy / methods

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810561.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


43. Jimenez AM: Laparoscopically assisted vulvocolpohysterectomy and abdominoperineal resection with sigmoid vaginal replacement. J Minim Invasive Gynecol; 2010 May-Jun;17(3):379-82
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In this report, we discuss the feasibility of laparoscopy for the resection of recurrent invasive vulvar cancer involving the vagina and anus (stage IVA), requiring radical surgical treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Colon, Sigmoid / surgery. Hysterectomy / methods. Laparoscopy / methods. Neoplasm Recurrence, Local / surgery. Vagina / surgery. Vulvar Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AAGL. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20417431.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Tilney HS, Heriot AG, Trickett JP, Massouh H, Edwards DP, Mellor SG, Gudgeon AM: The use of intra-operative endo-anal ultrasound in perianal disease. Colorectal Dis; 2006 May;8(4):338-41
MedlinePlus Health Information. consumer health - Anal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of intra-operative endo-anal ultrasound in perianal disease.
  • Pathologies encountered were fistula-in-ano (42%), fissure-in-ano (26%), complicated perianal sepsis (16%) and carcinoma (5%).
  • In 22 cases (51.2%) the EAUS findings affected the surgical management (extent of muscle above a fistula 9 cases, extent of sphincterotomy 7 cases, site of sepsis identified 2 cases, exclusion of sepsis 2 cases, assessment of cancer resectability 1 case, biopsy of intersphincteric lesion 1 case).
  • While not essential, it is a useful adjunct especially in recurrent perianal sepsis, undiagnosed anorectal pain and anal fissure.
  • [MeSH-major] Anus Diseases / surgery. Anus Diseases / ultrasonography. Endosonography. Intraoperative Care. Rectal Fistula / surgery. Rectal Fistula / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630240.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


45. Handisurya A, Rieger A, Bago-Horvath Z, Schellenbacher C, Bankier A, Salat A, Stingl G, Kirnbauer R: Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient. Sex Transm Infect; 2009 Aug;85(4):261-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient.
  • BACKGROUND: Buschke-Löwenstein tumour (BLT) of the anogenitalia is a locally invasive, destructively growing verrucous carcinoma that does not metastasise.
  • Nevertheless, the tumour grows relentlessly and may rarely progress into squamous cell cancer (SCC).
  • RESULTS: A human immunodeficiency virus (HIV)-infected immunosuppressed patient developed (peri)anal warts accompanied by recurrent abscesses and fistulae.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. HIV Infections / complications. Immunocompromised Host
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. Anti-HIV Agents / therapeutic use. Cachexia / etiology. Fatal Outcome. Groin. HIV Seropositivity / drug therapy. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness


46. Balicevic D, Tomic K, Bekavac-Beslin M, Kovacevic I, Mijic A, Belicza M, Kruslin B: Synchronous anorectal melanoma. World J Gastroenterol; 2006 Jun 7;12(21):3453-5
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 75-years-old male patient who presented with a history of recurrent rectal bleeding, and whose histopathological diagnosis was melanoma.
  • [MeSH-major] Anus Neoplasms / diagnosis. Melanoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Rectal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg. 2000 Jul;166(7):583-4 [10965842.001]
  • [Cites] Cancer Control. 2002 Jan-Feb;9(1):9-15 [11907461.001]
  • [Cites] Dis Colon Rectum. 1982 Oct;25(7):693-703 [7128372.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):18-25 [8988722.001]
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] World J Gastroenterol. 2005 Apr 14;11(14):2197-9 [15810093.001]
  • (PMID = 16733870.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087884
  •  go-up   go-down


47. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol; 2007 Feb;14(2):478-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
  • BACKGROUND: The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy.
  • For patients who present with persistent or locally recurrent disease, salvage abdominoperineal resection is the treatment of choice.
  • RESULTS: Eleven patients underwent radical salvage surgery for persistent disease and 20 patients for recurrent disease.
  • Twelve patients developed recurrent disease after radical salvage surgery.
  • Factors that were not found to have an impact on survival included the presence of persistent versus recurrent disease, tumor (T) stage, and margin status of resection.
  • CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103253.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Palefsky JM: Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health; 2010 Apr;46(4 Suppl):S12-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cause of mortality related to human papillomavirus (HPV) infection is cervical cancer.
  • HPV is associated with a variety of cancers in men, including anal cancer and a subset of penile and oral cancers.
  • The incidence of anal and oral cancers related to HPV is increasing in the general population and is growing even faster among individuals who are immunocompromised because of human immunodeficiency virus (HIV) infection.
  • Likewise, anal HPV infection and anal intraepithelial neoplasia are very common throughout a wide range of ages in both HIV-negative and HIV-positive men who have sex with men.
  • Other HPV-related diseases of clinical importance in men include condylomata acuminata (genital warts) and recurrent respiratory papillomatosis.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Men's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antivir Ther. 2004 Feb;9(1):13-22 [15040532.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Infect Dis. 2004 Aug 1;190(3):468-76 [15243918.001]
  • [Cites] Sex Transm Dis. 2004 Oct;31(10):601-7 [15388997.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] Int J Cancer. 1989 Aug 15;44(2):199-203 [2547727.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] J Med Virol. 1991 Mar;33(3):159-64 [1652616.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2036-43 [18708396.001]
  • [Cites] J Infect Dis. 2008 Sep 15;198(6):827-35 [18657037.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2683-91 [18843010.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2883-91 [18980292.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):59-70 [19050387.001]
  • [Cites] J Infect Dis. 2009 Jan 1;199(1):7-13 [19086813.001]
  • [Cites] J Adolesc Health. 2009 Jan;44(1):33-40 [19101456.001]
  • [Cites] Int J Cancer. 2009 Mar 15;124(6):1251-7 [19089913.001]
  • [Cites] Clin Infect Dis. 2009 Mar 1;48(5):536-46 [19191636.001]
  • [Cites] World J Urol. 2009 Apr;27(2):141-50 [18607597.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1710-6 [16030106.001]
  • [Cites] Clin Infect Dis. 2005 Sep 1;41(5):612-20 [16080082.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2550-6 [16284377.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):326-33 [16492924.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1247-55 [16631880.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2645-54 [16790697.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):1-5 [16133005.001]
  • [Cites] Emerg Infect Dis. 2007 Jan;13(1):28-41 [17370513.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] Pediatr Infect Dis J. 2007 Mar;26(3):201-9 [17484215.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1107-14 [17548671.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-70 [17602732.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1128-36 [17955430.001]
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1322-8 [17923869.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] J Infect Dis. 2008 Apr 1;197(7):957-66 [18429348.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Emerg Infect Dis. 2008 Jun;14(6):888-94 [18507898.001]
  • [Cites] Sex Transm Infect. 2008 Jun;84(3):161-6 [18339658.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):345-52 [10888420.001]
  • [Cites] Sex Transm Infect. 2000 Jun;76(3):162-8 [10961190.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):189-93 [11144896.001]
  • [Cites] Laryngoscope. 2001 Jan;111(1):57-69 [11192901.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):705-11 [11875730.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1105-12 [11948269.001]
  • [Cites] Anticancer Res. 2009 May;29(5):1467-74 [19443352.001]
  • [Cites] AIDS. 2009 Jun 1;23(9):1135-42 [19390418.001]
  • [Cites] BMJ. 2009;339:b3884 [19815582.001]
  • [Cites] MMWR CDC Surveill Summ. 1992 Apr 24;41(2):1-7 [1594012.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1666-9 [8348498.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91 [7488368.001]
  • [Cites] Acta Derm Venereol. 1995 Nov;75(6):470-4 [8651027.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1060-7 [8683637.001]
  • [Cites] Int J STD AIDS. 1996 May-Jun;7(3):197-200 [8799782.001]
  • [Cites] J Infect Dis. 1997 Aug;176(2):353-61 [9237700.001]
  • [Cites] Sex Transm Dis. 1997 Nov;24(10):567-72 [9383844.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):744-54 [15599852.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):606-16 [15825185.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):351-7 [12196743.001]
  • [Cites] Sex Transm Infect. 2002 Jun;78(3):215-8 [12238658.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] J Infect Dis. 2003 Apr 1;187(7):1064-70 [12660920.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1397-403 [12766834.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • [Cites] J Infect Dis. 2004 Feb 15;189(4):677-85 [14767822.001]
  • [Cites] Med Microbiol Immunol. 2004 Feb;193(1):35-44 [12838415.001]
  • [ErratumIn] J Adolesc Health. 2010 Jun;46(6):614
  • (PMID = 20307839.001).
  • [ISSN] 1879-1972
  • [Journal-full-title] The Journal of adolescent health : official publication of the Society for Adolescent Medicine
  • [ISO-abbreviation] J Adolesc Health
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA054053-10; United States / NCI NIH HHS / CA / R01 CA054053; United States / NCI NIH HHS / CA / CA088739-05; United States / NCI NIH HHS / CA / R01 CA088739; United States / NCI NIH HHS / CA / R01 CA088739-05; United States / NCI NIH HHS / CA / R01 CA054053-10
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 91
  • [Other-IDs] NLM/ NIHMS180665; NLM/ PMC2871537
  •  go-up   go-down


49. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • Resection is now reserved for persistent or recurrent disease.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Haboubi NY, Edilbe MW, Hill J: Justification for staging of epidermoid anal carcinoma after salvage surgery: a pathological guideline. Colorectal Dis; 2007 Mar;9(3):238-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Justification for staging of epidermoid anal carcinoma after salvage surgery: a pathological guideline.
  • The currently accepted first line treatment for epidermoid anal cancer is chemoradiotherapy (CRT).
  • Residual or recurrent disease following initial CRT, is best treated by salvage anorectal excision.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Neoplasm Staging / standards

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298622.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Tokar M, Bobilev D, Zalmanov S, Geffen DB, Walfisch S: Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. Onkologie; 2006 Feb;29(1-2):30-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature.
  • BACKGROUND: We report on a patient with squamous cell anal carcinoma and liver metastases, who underwent multimodal treatment for cure, consisting of repeated partial hepatectomy in combination with chemoradiotherapy.
  • PATIENTS AND METHODS: A 54-year-old woman presented with squamous cell anal carcinoma and liver metastases.
  • 2 and 5 years after presentation, the patient underwent repeated partial hepatectomies for recurrent liver disease.
  • RESULTS: Repeated partial hepatectomy led to prolonged survival in a patient with squamous cell anal carcinoma metastatic to the liver.
  • CONCLUSIONS: This is the first report of aggressive partial hepatectomy for recurrent liver metastases resulting from anal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2006 Feb;29(1-2):5-6 [16514247.001]
  • (PMID = 16514253.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


52. Iesalnieks I, Gaertner WB, Glass H, Strauch U, Hipp M, Agha A, Schlitt HJ: Fistula-associated anal adenocarcinoma in Crohn's disease. Inflamm Bowel Dis; 2010 Oct;16(10):1643-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fistula-associated anal adenocarcinoma in Crohn's disease.
  • We present 6 patients with CD and fistula-associated anal adenocarcinoma (FAAA) and a systematic review of published series.
  • Mean delay of cancer diagnosis was 11 months.
  • Thirteen of 15 patients with node-positive tumors died with recurrent disease following surgery.
  • Periodical cancer surveillance should be performed in all patients with long-standing perianal CD fistulae.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / etiology


53. Bell SW, Dehni N, Chaouat M, Lifante JC, Parc R, Tiret E: Primary rectus abdominis myocutaneous flap for repair of perineal and vaginal defects after extended abdominoperineal resection. Br J Surg; 2005 Apr;92(4):482-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Significant morbidity can result from perineal wounds, particularly after radiotherapy and extensive resection for cancer.
  • Twenty-six patients had surgery for recurrent or persistent epidermoid anal cancer or low rectal cancer, and 21 had high-dose preoperative radiotherapy.
  • [MeSH-minor] Adult. Aged. Anus Neoplasms / radiotherapy. Anus Neoplasms / surgery. Female. Humans. Length of Stay. Middle Aged. Neoplasm Recurrence, Local / surgery. Prospective Studies. Radiation Injuries / etiology. Radiotherapy / adverse effects. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery. Reoperation. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Surg. 2005 Aug;92(8):1046 [16034808.001]
  • (PMID = 15736219.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Zhi FC, Yue H, Jiang B, Xu ZM, Bai Y, Xiao B, Zhou DY: Diagnostic value of double balloon enteroscopy for small-intestinal disease: experience from China. Gastrointest Endosc; 2007 Sep;66(3 Suppl):S19-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Diseases of the small intestine include, among others, ulceration, chronic inflammation, Meckel's diverticula, vascular deformities, and cancer.
  • DESIGN: DBE was performed via the mouth, anus, or both approaches to diagnose small-intestinal disease.
  • These lesions found were small-intestinal ulcers (including Crohn's disease), chronic inflammation, Meckel's diverticulae, vascular deformities, and carcinoma.
  • In the 45 patients with small-intestinal ulcer, 29 patients had recurrent hemorrhage, 9 had abdominal pain, 4 had abdominal distention, 2 had malnutrition, and 1 had diarrhea.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709022.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement